MLYS Stock Forecast: Mineralys Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Mineralys Therapeutics, Inc. is $52. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 13 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Mineralys Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (64): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
MLYS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MLYS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $56 |
| 12 Oct 2026 | UBS | Initiates | Neutral | $29 |
| 27 Apr 2026 | TD Cowen | Initiates | Buy | — |
| 13 Mar 2026 | B of A Securities | Maintains | Buy | — |
| 19 Dec 2025 | Stifel | Maintains | Buy | — |
| 12 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Nov 2025 | Wells Fargo | Maintains | Overweight | — |
| 30 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Sept 2025 | Wells Fargo | Maintains | Overweight | — |
| 9 Sept 2025 | Goldman Sachs | Maintains | Buy | — |
| 8 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Sept 2025 | Jefferies | Maintains | Hold | — |
| 28 Aug 2025 | B of A Securities | Maintains | Buy | — |
| 13 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 June 2025 | Jefferies | Initiates | Hold | — |
| 13 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Apr 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Feb 2025 | Guggenheim | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MLYS.
This page is one stock. Monday covers all of them.
MLYS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
MLYS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Mineralys Therapeutics, Inc. returned −67.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
MLYS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 2.4×
- EV / EBITDA
- —
Cheaper than 37% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −68.5%
- Return on assets
- −39.6%
- Dividend yield
- —
Higher than 18% of US stocks
Higher than 10% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Mineralys Therapeutics, Inc. has a market value of $1.2B and an enterprise value of $683.3M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$349.6M.
Diluted earnings per share, trailing twelve months: −$4.24.
Free cash flow in the twelve months to 30 June 2026: −$138.8M.
Mineralys Therapeutics, Inc. employs 76 people.
Data provided by Twelve Data
MLYS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at MLYS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Mineralys Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about MLYS
What is the MLYS stock price forecast for 2026-2027?
The median 12-month analyst price target for Mineralys Therapeutics, Inc. is $52, with estimates ranging from $19 to $56. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MLYS stock a buy right now?
Of the 11 analysts covering Mineralys Therapeutics, Inc., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Mineralys Therapeutics, Inc. 13 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MLYS?
As at 21 Nov 2026, Mineralys Therapeutics, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (64 of 100).
Will MLYS stock go up?
No one can know that. What the data says: the median 12-month target from 11 analysts is $52, and Ticker Nerd's factor model ranks Mineralys Therapeutics, Inc. 13 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MLYS stock forecast for 2030?
No analyst covering Mineralys Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MLYS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $56 over the next 12 months.
How has MLYS stock performed over the past year?
Mineralys Therapeutics, Inc. returned -67.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Mineralys Therapeutics, Inc. do?
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for diseases driven by dysregulated aldosterone. Its lead product candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor being studied for cardiorenal conditions such as hypertension, chronic kidney disease, and obstructive sleep apnea.
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for diseases driven by dysregulated aldosterone. Its lead product candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor being studied for cardiorenal conditions such as hypertension, chronic kidney disease, and obstructive sleep apnea. Mineralys Therapeutics concentrates on the treatment of hypertension and related comorbidities, aiming to address patients who do not respond adequately to existing therapies. The company operates as a development-stage drugmaker with a pipeline centered on aldosterone-targeted treatment, combining clinical research, regulatory activity, and outsourced manufacturing and trial operations. Based in Radnor, Pennsylvania, Mineralys Therapeutics plays a specialized role in the biopharmaceutical market by advancing therapies for cardiometabolic and renal diseases with a focus on precision targeting of hormone-driven pathways.
CEO Dr. Jon Congleton · 76 employees · United States · https://mineralystx.com